evipedia.aidev
← Back

SAMe for Health & Longevity

Evidence Review created on 08/13/2026 using AI4L / Grok 4.5

Also known as: S-Adenosylmethionine, S-Adenosyl-L-methionine, AdoMet, SAM, SAM-e, Ademetionine

Motivation

SAMe (S-adenosylmethionine) is a molecule every human cell already makes from the amino acid methionine.
It donates single-carbon methyl groups to DNA, membranes, and brain signaling chemicals.
When that pool is low, mood, joint comfort, and liver resilience are the domains most often discussed.
A laboratory-made version is sold as a dietary supplement in the United States and as a prescription product in parts of Europe.

Interest comes from three places: decades of European hospital use for depression and arthritis, a biochemistry story that ties the same methyl groups to aging of the genome and of the liver, and a practical fact that the native molecule is fragile and expensive, so product quality and dose vary widely.
Some people use it instead of standard antidepressants or anti-inflammatory drugs; others use it as an add-on when those are incomplete.

This review examines the human evidence that oral SAMe changes mood, joint symptoms, and liver measures, the mania and drug-interaction risks that sit beside those claims, and the protocols, product forms, and monitoring choices that determine whether the chemistry on paper shows up in practice.

Benefits - Risks - Protocol - Conclusion

High-level overviews of SAMe as a methyl-donor supplement for mood, joints, and related pathways.

No dedicated SAMe article or episode was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Chris Kresser, or Lifespan.io; those platforms discuss methylation or related nutrients without a standalone SAMe treatment.

Grokipedia

  • S-Adenosyl methionine

    Encyclopedia-style page covering biosynthesis, depression, osteoarthritis, liver use, oral pharmacokinetics, enteric-coated salts, and bipolar-mania risk.

Examine

  • S-Adenosylmethionine

    Independent evidence grades for depression, osteoarthritis, and liver outcomes, plus dosing ranges, serotonergic interactions, and a bipolar-disorder contraindication.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses of SAMe for depression, liver disease, and osteoarthritis.

No systematic review with SAMe harms as the primary endpoint was identified; the Cochrane osteoarthritis review includes adverse-event analyses.

Mechanism of Action

SAMe is assembled from methionine and ATP (adenosine triphosphate, the cell’s energy currency) by methionine adenosyltransferase.
It then feeds three pathways: transmethylation, transsulfuration, and aminopropylation.
In transmethylation, SAMe donates its methyl group to DNA, proteins, membrane phospholipids, and neurotransmitters, then becomes S-adenosylhomocysteine and homocysteine.
Homocysteine is remethylated to methionine by methionine synthase (vitamin B12 and 5-methyltetrahydrofolate as cofactors) or converted via cystathionine-beta-synthase and vitamin B6 toward glutathione.
Aminopropylation supplies polyamines used in cell growth.
The compound is not a receptor-selective drug; it is a substrate for hundreds of methyltransferases, including COMT (catechol-O-methyltransferase, the enzyme that methylates dopamine and levodopa).
A competing account holds that pharmacologic doses also act through methylthioadenosine, a breakdown product that is not a methyl donor, and that surplus SAMe can be catabolized to adenine and thereby inhibit methylation.
The liver produces most circulating SAMe and is the main site of methionine metabolism.
Oral enteric-coated tosylate reaches peak plasma levels in about 5 hours, with a terminal half-life of about 6 hours and oral-to-intravenous exposure of roughly 2 percent; multiple daily doses do not accumulate (Yang et al., 2009).
Clearance is metabolic consumption, not cytochrome P450 oxidation.
Parenteral and oral forms both raise cerebrospinal-fluid SAMe, indicating central delivery despite low oral bioavailability.

Historical Context & Evolution

Giulio Cantoni isolated SAMe in 1952 as the cell’s principal methyl donor.
Italian and German clinicians turned the unstable natural molecule into injectable and later enteric-coated oral salts and, from the 1970s, used prescription ademetionine for depression, osteoarthritis, and intrahepatic cholestasis (impaired bile flow).
Early parenteral depression studies reported a rapid mood lift and, in bipolar patients, a switch into elevated mood (Carney et al., 1989).
After the Dietary Supplement Health and Education Act, oral SAMe entered the United States market as a supplement in 1999.
A two-year Spanish cirrhosis trial of 1,200 mg daily reported fewer deaths or transplants once Child-Pugh C (the most advanced clinical class) cases were excluded (Mato et al., 1999); several liver and psychiatry trials were supported by manufacturers of the pharmaceutical salt.
The Massachusetts General Hospital Depression Clinical and Research Program then tested oral SAMe as add-on and monotherapy.
Later syntheses split: one 2024 meta-analysis found a moderate monotherapy effect versus placebo (Limveeraprajak et al., 2024), another did not (Peng et al., 2024).
The current picture is not a settled consensus.
What changed is formulation (stable butanedisulfonate and tosylate salts), route (oral rather than injection), and the size of the controlled literature—not a single decisive experiment.

Expected Benefits

Medium 🟩 🟩

Depressive symptom reduction ⚠️ Conflicted

SAMe donates methyl groups used in serotonin, dopamine, and phospholipid synthesis.
A 2024 meta-analysis of 23 trials found monotherapy reduced depressive symptoms versus placebo, with similar dropout (Limveeraprajak et al., 2024).
A second 2024 meta-analysis found no significant monotherapy or add-on difference versus placebo (Peng et al., 2024).
An add-on trial in serotonin-reuptake-inhibitor nonresponders reported a higher response rate than add-on placebo (Papakostas et al., 2010).
Site and dose (200–3,200 mg/day) differences likely explain the split.

Magnitude: Standardized mean difference (a unitless measure of how far two group averages differ) −0.58 versus placebo in one 2024 meta-analysis (95% CI, a range likely to contain the true value, −0.93 to −0.23); a contemporaneous meta-analysis found no significant difference.

Osteoarthritis pain and function ⚠️ Conflicted

SAMe is thought to support cartilage proteoglycan synthesis and reduce inflammatory mediators in joint tissue.
A 2002 meta-analysis of 11 randomized trials found function better than placebo and pain and function comparable to NSAIDs (nonsteroidal anti-inflammatory drugs) (Soeken et al., 2002).
A later Cochrane review of four placebo-controlled trials found a small, non-significant pain difference and no function benefit (Rutjes et al., 2009).
A crossover trial found 1,200 mg/day as effective as celecoxib 200 mg after month 1 (Najm et al., 2004).

Magnitude: Pain standardized mean difference −0.17 versus placebo in Cochrane (95% CI −0.34 to 0.01), about 0.4 cm on a 10 cm visual analog scale; NSAID-comparable in the 2002 meta-analysis.

Liver laboratory values and compensated cirrhosis

Hepatic methionine adenosyltransferase falls in cirrhosis, lowering endogenous SAMe and glutathione.
A 2024 review of 15 studies reported improved liver laboratory values at 1,000–1,200 mg/day (Baden et al., 2024).
A 2015 meta-analysis found mixed bilirubin and AST (aspartate transaminase, a liver-injury enzyme) effects and no consistent ALT (alanine transaminase) or survival change (Guo et al., 2015).
A two-year 1,200 mg/day alcoholic-cirrhosis trial reduced death or transplant after excluding Child-Pugh C (most advanced class) (Mato et al., 1999).

Magnitude: In alcoholic cirrhosis without Child-Pugh C disease, 2-year death or transplant was 12% with SAMe versus 29% with placebo; including Child-Pugh C, the difference was not statistically significant.

Low 🟩

Fibromyalgia symptoms

Two small double-blind trials reported improvements in pain, fatigue, morning stiffness, and mood at 800 mg oral or with intravenous dosing, without a consistent tender-point change (Jacobsen et al., 1991).
Sample sizes were under 50.

Magnitude: In a 44-person oral trial, last-week pain, fatigue, and morning stiffness improved versus placebo and tender-point score did not; the literature reports no outcome figure.

Intrahepatic cholestasis (impaired bile flow)

SAMe has been used for pregnancy-associated cholestasis.
A meta-analysis found ursodeoxycholic acid (a bile-acid medication) plus SAMe reduced itch and bile acids more than either alone in some analyses (Zhang et al., 2016).
This is an obstetric liver indication, not a general longevity outcome.

Magnitude: Combination regimens lowered itch scores and serum bile acids in pregnancy-cholestasis trials, with smaller, inconsistent monotherapy effects; the literature reports no outcome figure.

Speculative 🟨

Cognitive aging and DNA methylation

A 2023 meta-analysis of human and animal randomized trials found no overall cognitive benefit (Zhao et al., 2023).
Any longevity claim rests on methylation biology, not lifespan trials.

Benefit-Modifying Factors

  • MTHFR variants: MTHFR (methylenetetrahydrofolate reductase, the enzyme that makes active folate) variants can shrink the endogenous SAMe pool. Low folate or B12 leaves more biochemical room to respond.
  • Baseline methylation status: Low plasma SAMe, high homocysteine, or low folate/B12 are the settings in which supplementation is most often studied. Replete one-carbon status (the folate–B12–methionine cycle that supplies methyl groups) leaves less to correct.
  • Sex: A re-analysis of one randomized trial suggested a larger antidepressant signal in men than women (Sarris et al., 2015). Oral pharmacokinetics did not differ by sex.
  • Pre-existing depression or liver disease: Benefit signals concentrate in major depression and chronic liver disease, not in unselected healthy adults seeking a general longevity regimen. An uncontrolled 13-person Parkinson’s series also reported mood improvement (Di Rocco et al., 2000).
  • Age: Osteoarthritis and cirrhosis trials enrolled older adults. Hepatic methionine adenosyltransferase falls with liver injury more than with calendar age alone.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Manic or hypomanic mood switch

SAMe can precipitate elevated mood in bipolar-spectrum illness.
In an open series, 9 of 11 bipolar patients switched after SAMe (Carney et al., 1989).
A healthy-volunteer pharmacokinetic study recorded a mixed manic state with suicidal ideation at 1,600 mg/day that resolved within 3 days of stopping (Goren et al., 2004).
An early oral depression trial also induced mania in a patient without prior mania (Kagan et al., 1990).
The switch reversed with discontinuation in reported cases.

Magnitude: In the Carney series, 9 of 11 bipolar patients switched into hypomania, mania, or euphoria; unipolar patients did not switch.

Gastrointestinal intolerance

Nausea, diarrhea, constipation, and abdominal discomfort are the most frequent adverse events across randomized trials and systematic reviews (Baden et al., 2024).
Rates often resemble placebo.
Enteric coating reduces gastric exposure.
Symptoms are usually mild and transient.

Magnitude: Nausea and other gastrointestinal effects are the most frequent adverse events and often resemble placebo rates; the literature reports no pooled gastrointestinal-specific incidence figure (Baden et al., 2024).

Medium 🟥 🟥

Anxiety, insomnia, and agitation

Stimulant-like effects—anxiety, irritability, insomnia, sweating, and dizziness—appear in product labels and trial reports (Kagan et al., 1990).
These are typically dose-related and more common at 1,600 mg/day and above.
Earlier-in-the-day dosing is used to limit sleep disruption.

Magnitude: Insomnia, anxiety, and irritability are among the most common non-gastrointestinal effects, typically at 1,600 mg/day and above; the literature reports no outcome figure.

Serotonergic toxicity with antidepressants

Combining SAMe with SSRIs (selective serotonin reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), or other serotonergic agents is flagged for serotonin syndrome (agitation, high fever, clonus—rhythmic muscle jerks).
Case literature exists; some randomized trials still used SAMe as an add-on without that event (Papakostas et al., 2010).
Severity is labeled high despite uncertain frequency.

Magnitude: Not quantified in available studies. Controlled trials were not powered for rare toxicity, so incidence is known only from case reports.

Low 🟥

Reduced levodopa effect

COMT uses SAMe as the methyl donor.
Extra SAMe can theoretically accelerate levodopa clearance and worsen motor control.
An open Parkinson’s depression series still reported mood benefit (Di Rocco et al., 2000).

Magnitude: Not quantified in available studies. No controlled trial has measured the change in levodopa pharmacokinetics during oral SAMe.

Pneumocystis infection in immunocompromised people

Pneumocystis, a fungus that can cause pneumonia when immunity is weak, scavenges host SAMe.
A microbiology review describes this dependence and the concern that extra SAMe could support growth (Merali & Clarkson, 2004).
Human supplementation trials have not measured this infection endpoint.

Magnitude: Not quantified in available studies. No controlled trial has measured Pneumocystis incidence during oral SAMe.

Speculative 🟨

Excess methylation via adenine

Cell work shows surplus SAMe can be broken down to adenine and thereby inhibit methylation, the opposite of the intended effect (Fukumoto et al., 2022).
Human relevance at ordinary oral doses is unknown.

Risk-Modifying Factors

  • COMT and MTHFR variants: Fast COMT methylators may deplete SAMe faster and shift catecholamines. MTHFR variants plus low folate raise baseline homocysteine and change the SAMe/S-adenosylhomocysteine ratio.
  • Homocysteine and B vitamins: If B12 or folate is low, donated methyl groups can raise homocysteine. A 1,600 mg/day volunteer study found no homocysteine rise (Goren et al., 2004).
  • Sex: Pharmacokinetics did not differ by sex (Yang et al., 2009). Mania-switch reports are not clearly sex-specific.
  • Bipolar or Parkinson’s disease: Bipolar spectrum is the main high-risk psychiatric group. Parkinson’s disease adds levodopa and COMT complexity.
  • Immunocompromise: Advanced T-cell suppression raises a theoretical Pneumocystis risk if extra SAMe feeds that organism.
  • Age: Older adults more often combine NSAIDs, antidepressants, and levodopa, which raises interaction risk more than calendar age itself.

Key Interactions & Contraindications

  • SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors; sertraline, escitalopram, venlafaxine): Caution — possible serotonin syndrome. Some trials used add-on SAMe; still a labeled interaction. Monitor for agitation, tremor, and fever.
  • MAOIs (phenelzine, tranylcypromine): Absolute contraindication in most references — serotonergic crisis risk. A washout matching the MAOI label is the usual mitigation.
  • Tricyclic antidepressants (imipramine, amitriptyline): Caution — used as comparators and occasional combinations; still serotonergic. Monitor mood and autonomic signs.
  • Tramadol, triptans, St. John’s wort, 5-hydroxytryptophan, L-tryptophan: Caution — additive serotonergic load. Separate or avoid the combination.
  • Antipsychotics (olanzapine, risperidone) and amphetamines (lisdexamfetamine): Caution — added serotonergic load and mood-switch overlap. Monitor for agitation, fever, and mixed mood.
  • Dextromethorphan: Caution — this over-the-counter cough suppressant can add serotonergic load. Avoid combining it with SAMe during a cold-remedy course.
  • Levodopa: Caution — increased methylation may reduce levodopa effect. Monitor motor symptoms and involve the prescribing neurologist.
  • Over-the-counter NSAIDs (ibuprofen, naproxen): Monitor — no major pharmacokinetic clash; additive gastrointestinal irritation is possible. Enteric-coated SAMe and meal timing can limit gastrointestinal load.
  • Folate, vitamin B12, and vitamin B6: Potentiating — support remethylation and transsulfuration and are used to limit homocysteine after SAMe donates its methyl group.
  • 5-methyltetrahydrofolate: Potentiating — raises endogenous SAMe production and is sometimes used instead of, or with, exogenous SAMe.

Populations who should avoid SAMe:

  • Bipolar I or II, or any prior antidepressant-induced mania or hypomania
  • Concurrent MAOI therapy
  • Parkinson’s disease treated with levodopa without specialist co-management
  • Advanced immunocompromise (for example untreated HIV (human immunodeficiency virus) with CD4 (helper T-cell count) below 200 cells/µL) without specialist co-management
  • Pregnancy outside a dedicated obstetric cholestasis protocol (early-pregnancy data are sparse)
  • Known hypersensitivity to SAMe tosylate, butanedisulfonate, or tablet excipients

Risk Mitigation Strategies

  • Low start with slow titration: 200–400 mg daily, then 200–400 mg every 1–2 weeks toward 800–1,600 mg, to reduce gastrointestinal effects and catch early mood activation.
  • Enteric-coated empty-stomach dosing: Protects the labile salt from gastric acid and lowers nausea compared with uncoated tablets.
  • Morning and early-afternoon split: Last dose by mid-afternoon to limit insomnia from the stimulant-like activation signal.
  • Bipolar-history screen: Avoids the highest-severity harm, manic switch, before the first tablet.
  • B12 and folate co-support: Limits homocysteine accumulation after transmethylation when baseline one-carbon status is low.
  • Hold extra serotonergic combinations: Separates SAMe from 5-hydroxytryptophan, St. John’s wort, and MAOIs to cut serotonin-syndrome risk.
  • Immunocompromise screen: Avoid unsupervised use when CD4 is very low or immunity is otherwise severely reduced, matching the Pneumocystis concern.
  • Mood check-ins in the first 2 weeks: The volunteer manic event occurred by week 2; early review catches activation or mixed states.

Therapeutic Protocol

  • Depression-range oral protocol: 800–1,600 mg/day enteric-coated, often split. The Massachusetts General Hospital add-on trial used 800 mg twice daily (Papakostas et al., 2010).
  • Joint-range protocol: 1,200 mg/day (400 mg three times) as in the celecoxib crossover; some later tapers toward 400 mg maintenance.
  • Liver-range protocol: 1,000–1,200 mg/day. Mato and the Indiana cirrhosis trial use 1,200 mg (800 mg morning, 400 mg evening) before meals.
  • Competing approaches: Conventional: prescription antidepressants or NSAIDs. Integrative: SAMe monotherapy or add-on (Fava/Papakostas/Mischoulon at Massachusetts General Hospital; European prescription ademetionine). Neither is framed as default.
  • Time of day: Morning and early afternoon, about 30 minutes before meals on an empty stomach, matching current trial instructions.
  • Half-life: Oral terminal half-life about 6 hours after enteric-coated tosylate; peak about 5 hours; oral bioavailability about 2% versus intravenous (Yang et al., 2009).
  • Split versus single dose: Split doses match the short half-life and the tablet load at 1,200–1,600 mg.
  • Genetics: MTHFR C677T with low folate favors ensuring 5-methyltetrahydrofolate and B12 rather than changing the SAMe milligram target.
  • Sex: No pharmacokinetic dose split. One re-analysis found a stronger mood signal in men (Sarris et al., 2015).
  • Age: Same milligram ranges in older osteoarthritis and cirrhosis cohorts; watch polypharmacy more than the calendar age.
  • Baseline biomarkers: Confirm B12, folate, homocysteine, and (for liver use) ALT, AST, and bilirubin before titrating.
  • Pre-existing conditions: Active major depression or compensated liver disease is where protocols were built. Bipolar illness is an exclusion, not a dose adjustment.

Discontinuation & Cycling

  • Duration: Used for 4–12 weeks in most psychiatry trials and up to 2 years in cirrhosis. Not established as lifelong in healthy adults.
  • Withdrawal: No classic discontinuation syndrome is described. One manic state resolved within 3 days of stopping (Goren et al., 2004).
  • Taper: Not required for a short half-life. A 3–7 day step-down after high doses is sometimes used to watch mood.
  • Cycling: No evidence that cycling preserves efficacy. Continuous daily use is how trials were run.

Sourcing and Quality

  • Salt and coating: Tosylate disulfate or 1,4-butanedisulfonate; enteric coating is required because native SAMe is acid-labile and degrades in the stomach.
  • Packaging: Blister cards, not bottles, to limit heat and moisture. Open bottles lose potency faster than foil-sealed tablets.
  • Third-party testing: ConsumerLab’s 2024 panel found listed content and coating on tested brands, but Amazon spot-checks have found zero-content products.
  • Brands in independent panels: Doctor’s Best, Jarrow Formulas, Life Extension, Nature Made, and Pure Encapsulations appeared in the ConsumerLab 2024 set.
  • Form: Oral enteric tablets are the consumer form. Intravenous or intramuscular 400 mg is a European prescription route, not a United States supplement.

Practical Considerations

  • Time to effect: Mood: some separation by week 1–2. Joints: slower than celecoxib, similar by month 2. Liver enzymes: weeks to months.
  • Common pitfalls: Non-enteric tablets, humid bottle storage, underdosing (200 mg when trials used 800–1,600 mg), and combining extra serotonergic supplements.
  • Regulatory status: Dietary supplement in the United States since 1999. Prescription ademetionine in parts of Europe and Asia for depression, joints, and cholestasis.
  • Cost: Relatively expensive. ConsumerLab reported about 47 cents to more than $2 per 400 mg of a passing product.
  • Payer incentives: United States insurers generally reimburse generic antidepressants and NSAIDs but not over-the-counter SAMe, a structural reason formularies and funded trials favor the covered drugs.

Interaction with Foundational Habits

  • Sleep: Direct, can disrupt. Insomnia and activation are labeled effects if the last dose is late. Morning and early-afternoon timing is the practical adjustment; no evidence it improves sleep architecture.
  • Nutrition: Direct, potentiating. Endogenous SAMe depends on methionine, folate, B12, and B6. Low-protein or vegan diets plus MTHFR variants may shrink the pool; pairing with methyl-folate and B12 is the usual nutritional context.
  • Exercise: Indirect, possibly potentiating. No evidence it blunts hypertrophy. Joint-pain reduction, if present, may support training volume. No specific peri-workout timing.
  • Stress management: Indirect, mixed. Mood effects overlap with stress load. Activation or anxiety in some users can work against down-regulation practices; there is no demonstrated cortisol mechanism.

Monitoring Protocol & Defining Success

Before the first dose, a bipolar-spectrum history and a one-carbon and liver panel establish whether SAMe is even a candidate and what the biochemical starting point is.
Homocysteine, B12, and folate show whether remethylation can keep up after extra methyl groups are supplied.
ALT, AST, and bilirubin are the liver-response and safety set used in the cirrhosis literature.
Ongoing checks at 2 weeks (mood and sleep only), 4–8 weeks (symptoms plus labs if the use-case is liver), then every 3 months for the first year and every 6–12 months thereafter, match the time-to-effect windows in depression, joint, and liver trials.
Success is a durable drop in the person’s own depression or joint scores, or a downward trend in cholestatic labs, without new activation, insomnia, or gastrointestinal dropout.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Homocysteine <8 µmol/L Tracks whether donated methyl groups are being recycled Fasting morning draw; pair with B12 and folate. Conventional often <15 µmol/L
Vitamin B12 500–1,000 pg/mL Cofactor for methionine synthase Add methylmalonic acid if serum B12 is borderline. Conventional ~200–900 pg/mL
Folate (red-cell) Upper half of the laboratory range Substrate for remethylation to methionine Serum folate swings with recent intake; red-cell folate is more stable
ALT / AST Low-normal (often <25–30 U/L) Liver response and safety Fasting not required; interpret as a trend from the person’s baseline. Conventional upper limits ~40–55 U/L
Total bilirubin Within the laboratory range, falling if cholestatic Bile-flow response Pair with alkaline phosphatase and GGT (gamma-glutamyl transferase, a bile-duct enzyme)
Mood score (PHQ-9 or equivalent) No established target; track improvement from the person’s own baseline Detects benefit and activation PHQ-9 is the Patient Health Questionnaire-9. Daily journal for the first 2 weeks, then at each lab visit

Qualitative markers:

  • Sleep onset and nighttime awakenings after afternoon doses
  • Irritability, racing thoughts, or unusually elevated mood
  • Joint stiffness on waking and pain during usual training
  • Energy and cognitive clarity across the day
  • Nausea, loose stool, or abdominal cramping after tablets

Emerging Research

  • Alcoholic-cirrhosis mortality trial: NCT04250259 is a recruiting Phase 2 study (n=196) of 1,200 mg/day versus placebo for 24 months, with all-cause mortality as the primary endpoint. A clear result would strengthen or weaken the Mato survival signal.
  • MASLD-cirrhosis cancer-prevention trial: NCT07495995 is a not-yet-recruiting Phase 2 study (n=94) of 1,200 mg/day for 12 months in MASLD (metabolic dysfunction-associated steatotic liver disease). The primary endpoint is a prognostic liver-secretome score.
  • Colorectal-adenoma chemoprevention: NCT07582003 is a not-yet-recruiting Phase 1 study (n=18). A null or harmful signal would weaken methylation-based cancer-prevention claims.
  • Hand osteoarthritis pilot: NCT05363020 is a completed Phase 4 crossover (n=40, 400 mg twice daily) without posted results. It could update the inconclusive Cochrane knee-and-hip pain estimate.
  • Excess-SAMe biology: Fukumoto et al., 2022 showed surplus SAMe can inhibit methylation via adenine. If that holds in humans, high-dose protocols would look less attractive.

Conclusion

SAMe is a sulfur-containing metabolite the body makes from methionine and uses as its main methyl donor.
People take a laboratory-made version for mood, joint comfort, and liver function, and speculatively to feed DNA and membrane methylation that decline with age.

The strongest signal is in depressive symptoms, but two recent reviews disagree on whether the compound beats placebo when used alone.
Joint-pain data are split between older comparisons with anti-inflammatory drugs and a later review that found only a small, uncertain effect.
Liver studies show laboratory improvement more consistently than a clear survival effect, and the long cirrhosis experiment helped mainly people not yet in the most advanced disease class.
Gastrointestinal upset is common and usually mild.
The distinctive harm is a switch into mania in people with bipolar-spectrum illness, including at least one case with no prior mania.
Combining SAMe with other serotonin-raising drugs remains a caution even though some depression studies used it as an add-on.

Quality of the evidence is moderate and uneven: many older studies were small, oral absorption of enteric-coated salts is only a few percent of an intravenous dose, some liver and psychiatry literature was supported by manufacturers of the pharmaceutical salt, and insurers more often cover generic mood and joint drugs than over-the-counter SAMe.
For a health-optimizing adult who is not bipolar, not on a monoamine-oxidase inhibitor, and willing to use an unstable, costly acid-protected product, SAMe is a methyl-donor intervention with a real but contested signal—not a general longevity drug.

Top - Benefits - Risks - Protocol